Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
361-380 of 1,694 trials

Colchicine for Heart Health After PCI

We are studying whether colchicine can help reduce serious heart events in patients with coronary artery disease after a heart procedure. This trial compares colchicine to a placebo to see its effects on heart health.

Coronary Artery DiseaseConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyInternal Medicine

Spironolactone for Arrhythmogenic Right Ventricular Dysplasia (ARVD)

We are studying whether spironolactone can help reduce heart deterioration and arrhythmias in patients with ARVD. This trial compares its effects to a placebo over one and three years.

Arrhythmogenic Right Ventricular Dysplasia>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Juvenile Idiopathic Arthritis: Upadacitinib Study

We are evaluating the safety and how the body processes upadacitinib in children with polyarticular course juvenile idiopathic arthritis. The study also examines how well children tolerate the medication and its taste.

Juvenile Idiopathic Arthritis>2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboStandard MedicinesPediatricsRheumatology

Advanced Solid Tumors: Amivantamab Treatment Study

We are studying a new treatment called amivantamab for patients with advanced or metastatic solid tumors, including those with EGFR-mutated lung cancer. The goal is to see how well it works when combined with other therapies.

Non-small Cell Lung CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Non-Squamous NSCLC: Dato-DXd with Rilvegostomig

We are studying if a new treatment combination is safe and effective compared to pembrolizumab for patients with advanced non-squamous lung cancer. This trial is for those with high PD-L1 levels and no specific genetic changes.

Non-Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

ASP1570 for Advanced Solid Tumors

We are studying a new treatment, ASP1570, alone and with pembrolizumab for adults with advanced solid tumors. The trial aims to evaluate safety, tolerability, and potential anti-tumor effects.

Advanced Solid TumorsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

UDCA for Visual Recovery After Retinal Detachment Surgery

We are studying whether UDCA can improve vision recovery in patients who have had surgery for retinal detachment. The trial also looks at the treatment's safety and other effectiveness measures.

Rhegmatogenous Retinal Detachment≤3 monthsConfirmation phase (III)Standard MedicinesOphthalmology

Lung Cancer: Avutometinib and Sotorasib Study

We are testing a combination of two medications for patients with KRAS G12C mutant non-small cell lung cancer. The goal is to find the best dose and see how well it works and how safe it is.

Non-small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Uveitis Treatment: Adalimumab vs. Mycophenolate Mofetil

We are studying whether adalimumab can improve outcomes for people with steroid-dependent non-infectious uveitis compared to the standard treatment. This trial will help us understand the effectiveness and safety of both medications.

Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Cholestyramine for Obese Women: Pollutant Levels Study

We are exploring how cholestyramine treatment impacts harmful pollutant levels in obese women who may undergo bariatric surgery. This study aims to understand its effects before and after the surgery.

Epidermolysis Bullosa≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyEndocrinologyInternal Medicine

Childhood Onset Nephrotic Syndrome: Obinutuzumab vs. MMF

We are studying whether obinutuzumab is more effective and safer than MMF for children with childhood onset idiopathic nephrotic syndrome. We will also look at how these treatments affect fatigue and quality of life.

Childhood Idiopathic Nephrotic Syndrome1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Pyridoxine for Primary Sclerosing Cholangitis

We are studying whether pyridoxine can lower liver enzyme levels in people with primary sclerosing cholangitis. The trial will also look at its effects on vitamin B6 levels, liver function, and quality of life.

Primary Sclerosing Cholangitis≤3 monthsEfficacy phase (II)Standard MedicinesGastroenterologyHepatology

Spinal Muscular Atrophy: Risdiplam for Children

We are studying the effectiveness and safety of risdiplam in children with spinal muscular atrophy who have not improved after gene therapy. This research aims to see if risdiplam can help these patients regain function.

Spinal Muscular Atrophy (SMA)>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Duchenne Muscular Dystrophy: GNT0004 Gene Therapy

We are testing a new gene therapy for boys with Duchenne Muscular Dystrophy who can walk. The study aims to find the right dose and evaluate the therapy's safety and effectiveness compared to a placebo.

Duchenne Muscular DystrophySafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineNeurologyPediatrics

Combination Therapies for Advanced Esophageal Cancer

We are studying new treatment combinations for patients with advanced esophageal cancer who have already been treated with PD-1/PD-L1 therapies. The aim is to evaluate their safety and how well they work in shrinking tumors and improving survival.

Advanced Esophageal Squamous Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteOncology

Multiple Myeloma: Innovative Treatment Approaches

We are studying new methods to monitor multiple myeloma in patients who have not yet been treated. This trial compares different treatment combinations, including a stem cell transplant, to see which is more effective.

Multiple Myeloma6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia

We are comparing a new treatment, bomedemstat, to hydroxyurea in people with essential thrombocythemia who haven't been treated before. The goal is to see which treatment better reduces symptoms and fatigue.

Essential Thrombocythemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteHematology

Blood Pressure Response: Multi-Omics Study

We are exploring how specific biomarkers can predict the effectiveness of blood pressure medications for individuals. This study aims to improve treatment personalization and understand potential side effects.

Essential Hypertension3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Acute Myeloid Leukemia: MP0533 Treatment Study

We are testing a new drug, MP0533, for patients with acute myeloid leukemia or myelodysplastic syndrome. The study aims to evaluate its safety and how well it may work against these blood cancers.

Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)Safety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Glioblastoma Treatment: Lomustine with or without Reirradiation

We are studying whether adding a second round of radiation to lomustine improves survival and quality of life for patients with recurrent glioblastoma. This trial aims to find out if this combination is more effective than lomustine alone.

Glioblastoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology